Stockreport

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chro [Read more]